Discovery scientists were the first to validate cryopreserved tissue dissociations as a viable alternative to sourcing fresh tissue for many research applications. With proprietary custom protocols, our scientists have consistently demonstrated high percentages of viable cells both pre-freeze (81.3%) and post-thaw (69.7%). We also have found that most cell types are largely unaffected by cryopreservation. Click to access the white paper confirming cell viability in Dissociate Tumor Cells (DTCs) via flow cytometry.
Our team conducted a flow cytometry analysis of over 400 tumor dissociations across 11 oncology indications to observe indication-specific trends in tumor compositions. The data from this large-scale flow cytometry analysis of tumor dissociations has been presented at scientific meetings.
Also, a Technical Note is now available that confirms the suitability of DTCs for downstream genomic analysis by whole exome and whole transcriptome sequencing.
We continually innovate the utility of tissue dissociations in contemporary research and downstream applications (Box 1). Leveraging sophisticated technologies and techniques, including flow cytometry and genomic applications, we are expanding our sample characterizations and laboratory services. Exploring these applications in R&D and through client partnerships, our team has cultivated a deep expertise in applying tissue dissociations to custom projects. We are available for consultations to optimize the results of studies involving our tissue dissociations.